ACR

With numerous national and international meetings taking place throughout the year, choosing which conferences to attend can be difficult. While scientific programs remain a major draw, opportunities for networking, collaboration, career development and presenting research are often just as valuable. To help identify the meetings making the biggest impact across rheumatology, we asked members of the touchIMMUNOLOGY community to share the conferences they're prioritizing this year and what makes them worth attending.

At the American College of Rheumatology (ACR) Convergence 2025, Dr. Pamela Weiss delivered a focused presentation on the diagnosis and management of axial juvenile spondyloarthritis (axJSpA), highlighting key distinctions and overlaps with adult-onset disease. This targeted article synthesizes the principal objectives ...

Autoimmune rheumatic diseases (AIRDs) predominantly affect women during their reproductive years and are associated with increased risks of infertility and adverse pregnancy outcomes (APOs). These diseases, such as systemic lupus erythematosus (SLE), antiphospholipid antibody syndrome (APS) and rheumatoid arthritis (RA), ...

Can remission in axial spondyloarthritis be maintained after treatment withdrawal? In this interview from EULAR 2026, Prof. Atul Deodhar discusses findings from an analysis of the phase 3 SELECT-AXIS 2 trial, exploring clinical outcomes in patients who discontinued upadacitinib after achieving remission.

Could inhibiting B cells, rather than depleting them, offer a new approach to treating IgG4-related disease? In this interview from EULAR 2026, Dr Emanuel Della Torre discusses the unmet needs in IgG4-RD, the unique mechanism of the investigational therapy obexelimab, and key findings from the phase 3 INDIGO trial.

Overweight and obesity are common comorbidities in psoriatic arthritis (PsA) and can negatively affect disease activity and treatment response. The phase 3b TOGETHER-PsA trial evaluated the concomitant use of ixekizumab and tirzepatide in adults with PsA and overweight or obesity. In this interview, conducted at EULAR 2026, Dr Laura Coates (University of Oxford, Oxford, UK) discusses the rationale for this combination approach, highlights the study’s key findings, and considers their potential implications for the future management of PsA.

The US Food and Drug Administration (FDA) has approved deucravacitinib as the first tyrosine kinase 2 (TYK2) inhibitor for adults with active psoriatic arthritis (PsA), marking a new targeted treatment option for this chronic inflammatory disease. In the phase 3 POETYK PsA-1 and PsA-2 trials, the once-daily oral therapy significantly improved disease activity compared with placebo, with over half of treated patients achieving an ACR20 response at Week 16. By selectively inhibiting TYK2 signalling pathways involved in psoriatic disease, deucravacitinib offers a novel mechanism distinct from traditional JAK inhibitors, expanding its role beyond plaque psoriasis and introducing a new oral option for patients with PsA.

Interstitial lung disease (ILD) is recognized as one of the most frequent and potentially life-threatening pulmonary complications of systemic autoimmune rheumatic diseases (SARDs), a group of rare chronic inflammatory conditions characterized by autoimmune system dysregulation and chronic systemic inflammation. ILDs ...

As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchIMMUNOLOGY. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the immunology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year. Here are just some of the standout highlights from 2025.